A new genetic study on the causes of chronic kidney disease that combined multiple health measurements has led to a more comprehensive view of kidney function and the potential for targeted ...

AstraZeneca (AZ) has announced that a wider range of chronic kidney disease (CKD) patients across England and Wales will be able to access Forxiga (dapagliflozin), following updated final draft ...

Additionally, Arce anticipates positive commercial traction for Vafseo in the U.S. market, where it has secured broad access for nearly all U.S. dialysis patients, and is also monitoring its ...

The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending empagliflozin (Jardiance®) as an option for the treatment of eligible adults with ...

“The recommendation of Kapruvia ® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated ...